Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy
This article was originally published in The Tan Sheet
Executive Summary
The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: It will not have any real impact on industry. The bad news: It will not matter because pre-emption in the drug arena already took a body blow in the Supreme Court's Wyeth v. Levine ruling